Diabetes Drugs: Longer, Broader Phase II/III Trials Could Replace CV Outcomes Trials, US Panel Says

 
• By Sue Sutter
FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers